Virax Biolabs Group
VRAX
Virax Biolabs Group (VRAX) analyst forecast and price target
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| HC Wainwright & Co. | Maintained | Buy | $1.00 from $3.00 | Jan 9, 2026 |
| HC Wainwright & Co. | Initiated Coverage | Buy | $3.00 | Mar 31, 2025 |
Frequently asked questions
What is the latest analyst rating on VRAX?
On Jan 9, 2026, HC Wainwright & Co. maintained Virax Biolabs Group at Buy with a price target of $1.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.